| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.6 | 2.8 |
| Profit before tax | -64.2 | -33.2 |
| Net income | -64.5 | -33.2 |
| EPS (diluted, $ a share) | $-0.14 | $-0.24 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -42.9% |
|---|
10-Q filed with the SEC, NASDAQ: DBVT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
DBV Technologies S.A.: key numbers
- Share price
- $10.27Close, Nov 16
- Market cap
- $3.23B
- Shares outstanding
- 314.39MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from DBV Technologies S.A.
All →DBV Technologies Financial Results
DBV Technologies reported Q3 2026 financial results, highlighting the submission of its Biologics License Application (BLA) to the FDA for the Viaskin Peanut Patch in children aged 4-7 years. The company reported a cash position of $165.7 million, which is expected to fund operations into the third quarter of 2027 as it prepares for potential commercial launch.
- Term
- Q3 2026
“The third quarter marked a defining step in DBV’s evolution from a clinical-stage company into a commercial organization. With our BLA now submitted for children aged 4 through 7 years, and our planned BLA in toddlers aged 1 through 3 years, we are concentrating our efforts on the areas that will advance the company most meaningfully.”
Daniel Tassé, Chief Executive Officer of DBV Technologies
“We are grateful for the productive, ongoing dialogue with the FDA about both BLAs. As the regulatory dialogue progresses, we have every function across the company aligned on supporting a complete and efficient review of both dossiers, advancing manufacturing readiness alongside our contract manufacturing partner, and preparing to execute our launch plans with discipline.”
Daniel Tassé, Chief Executive Officer of DBV Technologies
DBV Technologies Other 8-K Filing
DBV Technologies has submitted a Biologics License Application (BLA) to the U.S. FDA for its VIASKIN Peanut Patch for children aged 4-7 years. The submission is based on positive Phase 3 VITESSE trial results and marks the company's transition toward a commercial-stage organization. The company has requested Priority Review for the application.
- Counterparty
- FDA